M&A Deal Summary |
|
|---|---|
| Date | 2023-07-03 |
| Target | Valneva - Clinical Trial Manufacturing Unit |
| Sector | Life Science |
| Buyer(s) | NorthX Biologics |
| Sellers(s) | Valneva |
| Deal Type | Divestiture |
SEARCH BY
NorthX Biologics develops and manufactures advanced biologics. The Company provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cell therapy and other advanced biologics. NorthX Biologics was founded in 1992 and is based in Matfors, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Sweden M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1998 |
| Sector | Life Science |
| Employees | 700 |
| Revenue | 170M EUR (2024) |
Valneva is a biotechnology company that focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Valneva was founded in 1998 and is based in Saint-Herblain, France.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Sweden M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-01-28 |
Vivalis SA
Nantes, France Vivalis is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. |
Buy | - |
